Diabetes and cancer, common threads and missing links.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic hypotheses and epidemiological associations without systematic methodology
PubMed 26879686 · doi:10.1016/j.canlet.2016.02.006
What was done
This narrative review synthesizes epidemiological and clinical evidence on the relationship between diabetes mellitus and cancer development. It examines shared risk factors such as obesity, proposed biological mechanisms, and the impact of anti-diabetic medications on cancer incidence and mortality.
What was found
The abstract provides no quantitative data or specific risk estimates. It reports several proposed pathophysiological mechanisms connecting diabetes to cancer: insulin resistance and hyperinsulinemia, enhanced inflammation, an aberrant metabolic state, endoplasmic reticulum stress, and deregulation of autophagy. It also notes that common risk factors like obesity and various anti-diabetic medications may modify cancer risk and prognosis.
Why it matters
Understanding the shared metabolic pathways and medication effects connecting type 2 diabetes and cancer helps frame strategies for primary prevention, early detection, and therapeutic selection in diabetic populations.
Limits
As a narrative review, it lacks a systematic search protocol, formal study quality assessment, or meta-analytic data synthesis. The abstract presents no numerical risk values or sample sizes, and does not differentiate risks across specific cancer types or individual medication classes.
Cited by
- supports Excess circulating insulin activates intracellular pathways leading to vascular smooth muscle proliferation, reduced cellular autophagy, and an increased risk of cancer.